About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Ovarian Cancer Clinical Trials in Dallas | 245 Studies

Clinical Trials Ovarian CancerDallas

Ovarian Cancer Clinical Trials in Dallas

Find 245 clinical trials for ovarian cancer near Dallas, Texas. Connect with research centers in your area.

All Ovarian Cancer trials nationwide All trials in Dallas

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 41-60 of 245 trials

UnknownThe Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid TumorsA Phase 1 Dose Escalation and Expansion Study of IMP7068 Monotherapy in Advanced Solid TumorsNCT04768868·Atlanta, Georgia and 15 others CompletedEffectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based ChemotherapyThe purpose of this study is to determine if an investigational drug called MORAb-003 is useful by itself or when used with other approved cancer drugs in treating women with…NCT00318370·San Diego, California and 19 others

Ovarian Cancer Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

Active not recruitingNivolumab and Ipilimumab in Treating Patients With Rare TumorsThis phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors.NCT02834013·Birmingham, Alabama and 1006 others

RecruitingDESTINY-PANTUMOUR04This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior…NCT07124000·Birmingham, Alabama and 17 others

TerminatedStudy of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene AmplificationsBBI-355 is an oral, potent, selective checkpoint kinase 1 (or CHK1) small molecule inhibitor in development as an ecDNA (extrachromosomal DNA) directed therapy (ecDTx).NCT05827614·Los Angeles, California and 15 others

RecruitingTesting Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian CancerThis phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination…NCT06580314·Birmingham, Alabama and 694 others

CompletedPhase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer.The main purpose of this study is to determine the safety and feasibility of weekly intra-peritoneal administration of Cantrixil to women with persistent or recurrent ovarian…NCT02903771·Oklahoma City, Oklahoma and 5 others

RecruitingA Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian CancerThis clinical trial evaluates how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for…NCT04251052·Birmingham, Alabama and 573 others

TerminatedA Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid TumorsThis is an open-label, non-randomized, Phase 1b/2 study to determine the safety and tolerability of NC410 when combined with a standard dose of pembrolizumab.NCT05572684·Tucson, Arizona and 16 others

CompletedStudy of XB002 in Subjects With Solid Tumors (JEWEL-101)This is a Phase 1, open-label, multicenter, dose-escalation and expansion study evaluating the safety, tolerability, PK, pharmacodynamics, and clinical antitumor activity of XB002…NCT04925284·Birmingham, Alabama and 94 others

CompletedS9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in RemissionRATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.NCT00003120·Mobile, Alabama and 92 others

TerminatedDose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid TumorsThis is a Phase 1, multicenter, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor…NCT04931823·Los Angeles, California and 7 others

Active not recruitingCarboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube CancerThis randomized phase III trial studies carboplatin given together with paclitaxel with or without bevacizumab to see how well it works compared with oxaliplatin given together…NCT01081262·Birmingham, Alabama and 247 others

TerminatedFenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian CancerThe purpose of this study is to determine the effectiveness of fenretinide (4-HPR/LXS) plus ketoconazole in the treatment of recurrent ovarian cancer or primary peritoneal…NCT01535157·Oklahoma City, Oklahoma and 2 others

CompletedA Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid TumorsThe primary purpose of this Phase 1, open-label study is to evaluate the safety, pharmacokinetics, and preliminary efficacy of ABBV-368 as a monotherapy and in combination with…NCT03071757·La Jolla, California and 26 others

RecruitingOpen-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced CancerIncyclix Bio (Incyclix) is developing INX-315 as an oral, small molecule inhibitor of cyclin dependent kinase 2 (CDK2) for the treatment of human cancers.NCT05735080·Orlando, Florida and 17 others

Active not recruitingTargeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)This phase II MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in patients with solid tumors, lymphomas, or multiple…NCT02465060·Birmingham, Alabama and 1409 others

TerminatedBatiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian CancerThis is a randomized, double-blind Phase 3 study to compare the efficacy and safety of batiraxcept (AVB-S6-500) in combination with paclitaxel (PAC) versus placebo in combination…NCT04729608·Mobile, Alabama and 149 others

Active not recruitingMirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal CancerGLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in participants…NCT05445778·Mobile, Alabama and 263 others

Active not recruitingLetrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerThis phase III trial studies how well letrozole with or without paclitaxel and carboplatin works in treating patients with stage II-IV low-grade serous carcinoma of the ovary…NCT04095364·Anchorage, Alaska and 908 others

PreviousPage 3 of 13Next

Other Conditions in Dallas

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia